Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

iwNHL 2015 | Monoclonal antibody therapies for cutaneous T-cell lymphoma

Name: Monoclonal antibody therapies for cutaneous T-cell lymphoma
Uploaded: 2015-10-03T00:00:00.000Z
Duration: 2 min 22 s
Description: At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Pier Luigi Zinzani, MD, PhD, of University of Bologna, Bologna, Italy, discusses the clinical development of the anti-CD30 antibody-drug conjugate brentuximab vedotin and the anti-CCR4 antibody mogamulizumab for the treatment of patients with cutaneous T-cell lymphoma.

Pier L. Zinzani • 3 Oct 2015

iwNHL 2015

Cutaneous T-Cell Lymphoma Non-Hodgkin Lymphoma Rare Diseases T-Cell Lymphoma Brentuximab vedotin Mogamulizumab

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Pier Luigi Zinzani, MD, PhD, of University of Bologna, Bologna, Italy, discusses the clinical development of the anti-CD30 antibody-drug conjugate brentuximab vedotin and the anti-CCR4 antibody mogamulizumab for the treatment of patients with cutaneous T-cell lymphoma.